YD Bio Statistics
Total Valuation
YD Bio has a market cap or net worth of $161.38 million. The enterprise value is $158.27 million.
| Market Cap | 161.38M |
| Enterprise Value | 158.27M |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
YD Bio has 70.32 million shares outstanding.
| Current Share Class | 70.32M |
| Shares Outstanding | 70.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 77.39% |
| Owned by Institutions (%) | 0.40% |
| Float | 15.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 316.22 |
| Forward PS | n/a |
| PB Ratio | 0.50 |
| P/TBV Ratio | 41.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 310.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.18, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.18 |
| Quick Ratio | 12.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,828.65 |
Financial Efficiency
Return on equity (ROE) is -42.69% and return on invested capital (ROIC) is -42.01%.
| Return on Equity (ROE) | -42.69% |
| Return on Assets (ROA) | -25.43% |
| Return on Invested Capital (ROIC) | -42.01% |
| Return on Capital Employed (ROCE) | -79.86% |
| Weighted Average Cost of Capital (WACC) | 3.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 6.65 |
Taxes
In the past 12 months, YD Bio has paid $25,080 in taxes.
| Income Tax | 25,080 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.94% in the last 52 weeks. The beta is -0.13, so YD Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -80.94% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 7.65 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 38,391 |
Short Selling Information
The latest short interest is 25,094, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 25,094 |
| Short Previous Month | 11,169 |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.16% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, YD Bio had revenue of $510,360 and -$1.41 million in losses. Loss per share was -$1.29.
| Revenue | 510,360 |
| Gross Profit | 155,356 |
| Operating Income | -1.46M |
| Pretax Income | -1.39M |
| Net Income | -1.41M |
| EBITDA | -5.06M |
| EBIT | -5.27M |
| Loss Per Share | -$1.29 |
Balance Sheet
The company has $3.13 million in cash and $22,265 in debt, with a net cash position of $3.11 million or $0.04 per share.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | 22,265 |
| Net Cash | 3.11M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 6.59M |
| Book Value Per Share | 4.57 |
| Working Capital | 3.20M |
Cash Flow
In the last 12 months, operating cash flow was -$1.84 million and capital expenditures -$74,914, giving a free cash flow of -$1.91 million.
| Operating Cash Flow | -1.84M |
| Capital Expenditures | -74,914 |
| Depreciation & Amortization | 104,735 |
| Net Borrowing | 181,874 |
| Free Cash Flow | -1.91M |
| FCF Per Share | -$0.03 |
Margins
Gross margin is 30.44%, with operating and profit margins of -286.45% and -276.58%.
| Gross Margin | 30.44% |
| Operating Margin | -286.45% |
| Pretax Margin | -271.67% |
| Profit Margin | -276.58% |
| EBITDA Margin | -848.19% |
| EBIT Margin | -883.31% |
| FCF Margin | n/a |
Dividends & Yields
YD Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.01% |
| Shareholder Yield | -4.01% |
| Earnings Yield | -0.87% |
| FCF Yield | -1.18% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
YD Bio has an Altman Z-Score of 104.61 and a Piotroski F-Score of 1.
| Altman Z-Score | 104.61 |
| Piotroski F-Score | 1 |